29th week of 2013 patent applcation highlights part 34 |
Patent application number | Title | Published |
20130183323 | TARGETED ANTIBIOTIC AND ANTIMICROBIAL TREATMENTS FOR PERSONALIZED ADMINISTRATION - A solution for the bottleneck issues in antibiotic treatment is to use novel antibiotic formulas with targeted delivery customized based on the nature of the infection and resistance profile of the infectious agent(s). | 2013-07-18 |
20130183324 | IMMUNOGENS FOR TREATMENT OF NEOPLASTIC AND INFECTIOUS DISEASE - The present invention relates to prophylactic and therapeutic methods of immunization against neoplastic and infectious diseases. The invention provides a method for identification of novel immunogens and compositions of such immunogens that are useful for eliciting immune responses against antigens associated with neoplastic or infectious diseases. | 2013-07-18 |
20130183325 | MUCOADHESIVE XYLOGLUCAN-CONTAINING FORMULATIONS USEFUL IN MEDICAL DEVICES AND IN PHARMACEUTICAL FORMULATIONS - Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients. | 2013-07-18 |
20130183326 | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF THE INTERLEUKIN-35 RECEPTOR COMPLEX - The receptor for Interleukin 35 (IL-35) is provided. The Interleukin 35 Receptor (IL-35R) comprises a heterodimeric complex of the Interluekin12Rβ2 receptor and the gp130 receptor. Various compositions comprising the IL-35R complex, along with polynucleotides encoding the same and kits and methods for the detection of the same the same are provided. Methods of modulating the activity of IL-35R or modulating effector T cell functions are also provided. Such methods employ various IL-35R antagonists and agonists that modulate the activity of the IL-35R complex and, in some embodiments, modulate effector T cell function. Further provided are methods for screening for IL-35R binding agents and for IL-35R modulating agents. Various methods of treatment are further provided. | 2013-07-18 |
20130183327 | COMPOSITIONS INCLUDING I-DOMAIN ANTIGEN CONJUGATE COMPOUNDS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISORDERS - The present disclosure provides IDAC compounds capable of presenting two or more signal 1 moieties to a host immune system and methods of using the IDAC compounds to treat or prevent autoimmune disorders in a subject. The present disclosure provides compounds including a modified I-domain peptide having two or more modified lysine residues and two or more signal 1 moieities conjugated to the modified lysine residues of the I-domain peptide and methods of using an making the compounds. | 2013-07-18 |
20130183328 | CANCER VACCINES AND VACCINATION METHODS - Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein. | 2013-07-18 |
20130183329 | Interferon-Inducing Porcine Reproductive and Respiratory Syndrome Virus Isolate - Provided are polynucleotides and proteins encoded by them which are useful for stimulating an immune response against Porcine reproductive and respiratory syndrome virus (PRRSV) in swine. The compositions can contain a newly discovered PRRSV strain or recombinant versions of it or polynucleotides isolated or derived from it, which can be provided as pharmaceutical preparations. | 2013-07-18 |
20130183330 | RECOMBINANT AVIAN INFECTIOUS CORYZA VACCINE AND PROCESS FOR PREPARING SAME - A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing | 2013-07-18 |
20130183331 | IMMUNOGENIC PROTEINS FROM GENOME-DERIVED OUTER MEMBRANE OF LEPTOSPIRA AND COMPOSITIONS AND METHODS BASED THEREON - outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the | 2013-07-18 |
20130183332 | Treatment and Prevention of Malaria - There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof. | 2013-07-18 |
20130183333 | INDUCED ACTIVATION IN DENDRITIC CELLS - The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide. | 2013-07-18 |
20130183334 | LENTIVIRAL VECTORS AND METHODS OF USE THEREOF - The compositions and methods described herein relate to lentiviral vectors that can be used to generate virions/viruses that exhibit enhanced infectivity with respect to monocyte-derived macrophages (MDM) and dendritic cells (MDDC). Such compositions and methods further relate to production of virions/viruses that can be used as components of vaccines that effectively stimulate innate immune responses. In a particular embodiment, compositions and methods described herein relate to production of virions/viruses that can be used as components of human immunodeficiency-1 (HIV-1) vaccines administered to stimulate innate immune responses to HIV-1. | 2013-07-18 |
20130183335 | RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA INFLUENZA VACCINE - The invention concerns a recombinant modified vaccinia virus Ankara (MVA virus) expressing at least two external influenza virus antigens and/or an epitope of one or more of the at least two antigens and at least two internal influenza virus antigens and/or an epitope of the at least two antigens. The invention, thus, concerns a recombinant MVA virus encoding multiple external and/or internal influenza virus antigens, preferably from multiple influenza virus strains. The invention further concerns the use of said recombinant MVA in preparing a medicament and vaccine for influenza virus. Further encompassed by the present invention are methods, composition and kits. | 2013-07-18 |
20130183336 | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology - The present invention relates to a life attenuated | 2013-07-18 |
20130183337 | KIT FOR THE PREPARATION OF A VACCINATING AGENT - A kit, a method of using it and a process for preparing a vaccine for immunization against the disease Porcine Circovirus Disease and/or Enzootic Pneumonia in pigs are proposed, in which a first container is only partly filled with a first vaccine and a second container is filled with a second vaccine, the second vaccine being transferred into the first container through an adapter device, when a closure device is penetrated for the first and/or only time, and the vaccinating agent is prepared therein, thus making the operation simple, less error-prone and more hygienic, while reducing the materials required. The adapter device has a pair of oppositely facing piercing elements formed of one of needles, hollow, spikes, wedges with at least one through passage extending through both piercing elements, each of the containers being pierced by a respective one of the piercing elements creating a fluid connection between the containers. | 2013-07-18 |
20130183338 | VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARIS, MYCOPLASMA HYOPNEUMONIAE AND PORCINE CIRCO VIRUS - The present invention pertains to a vaccine comprising in combination non-live antigens of | 2013-07-18 |
20130183339 | METHODS AND COMPOSITIONS INVOLVING IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES - Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2′ deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5′ or 3′ ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs. | 2013-07-18 |
20130183340 | INTRADERMAL INFLUENZA VACCINE - The invention relates to virosome-based influenza vaccines for the manufacture of medicaments that are administered intradermally in humans. The invention provides (trivalent) compositions comprising low doses of hemagglutinin (HA) antigen in a virosomal preparation that fulfill the immune response standards with respect to seroconversion rates, GMT-fold increase and protection rates, for use in vaccination set-ups. | 2013-07-18 |
20130183341 | INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING HEMAGGLUTININ PRODUCED WITHIN A PLANT - A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines. | 2013-07-18 |
20130183342 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR INFLUENZA - Described herein is the development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. It is disclosed herein that influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals. | 2013-07-18 |
20130183343 | System and Method of Preparing and Storing Activated Mature Dendritic Cells - The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like receptor agonists that induce clinically effective immune responses, preferably when used earlier in the disease process. The DCs of the present invention produce desirable levels of cytokines and chemokines, and further have the capacity to induce apoptosis of tumor cells. The cells can be cryopreserved and thawed for later use, thereby reducing the need for repeated pheresis and elutriation processes during vaccine production. These methods can also be utilized to directly target molecules involved in carcinogenetic signaling pathways and cancer stem cells. | 2013-07-18 |
20130183344 | RECOMBINANT VACCINE AGAINST CLOSTRIDIUM PERFRINGENS INFECTION AND EPSILON TOXIN INTOXICATION - The present invention relates to generation and high level expression of recombinant non-toxic of epsilon toxin of | 2013-07-18 |
20130183345 | Treatment of Bladder Cancer Following Detection of Expression Levels of Certain Progression Markers - Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis and treatment; particularly, determining the expression levels of protective markers (COL4A3BP, MBNL2, FABP4, NEK1 and SKAP2) and harmful markers (COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B) and making treatment decisions in consideration of increased or decreased risk of progression based on the marker expression levels. | 2013-07-18 |
20130183346 | UNIQUE TRANSCRIPTIONAL SIGNATURES IN THE BLOOD OF CLINICAL RESPONDERS - A method for using the blood transcriptional profile of patients with stage IV melanoma to generate networks associated with the possibility of prolonged survival and networks associated with clinical responses to dendritic cell (DC) vaccination as measured by tumor regression are disclosed herein. | 2013-07-18 |
20130183347 | Somatic Transgene Immunization and Related Methods - The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin molecule. The invention also provides a nucleic acid molecule comprising a hematopoietic expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide. The invention additionally provides a method of treating a condition by administering a nucleic acid molecule comprising a hematopoietic cell expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide, wherein the nucleic acid molecule is targeted to a hematopoietic cell. | 2013-07-18 |
20130183348 | Inhibitor of HMGB Protein-Mediated Immune Response Activation, and Screening Method - Provided are an inhibitor of activation of an immune response mediated by an HMGB protein, the inhibitor containing at least one compound selected from the group consisting of a phosphorothioate oligonucleotide and a derivative thereof, and a method of screening for an inhibitor or enhancer of activation of an immune response mediated by an HMGB protein, the method including a mixing step of mixing an HMGB protein and a labeled nucleic acid in the presence and absence of a test substance; a quantifying step of quantifying the HMGB protein bound to the labeled nucleic acid; and a determination step of determining that the test substance is an inhibitor of activation of an immune response mediated by the HMGB protein when the amount of the HMGB protein bound to the labeled nucleic acid in the presence of the test substance is less than the amount of the HMGB protein bound to the labeled nucleic acid in the absence of the test substance and determining that the test substance is an enhancer of activation of an immune response mediated by the HMGB protein when the amount of the HMGB protein bound to the labeled nucleic acid in the presence of the test substance is higher than the amount of the HMGB protein bound to the labeled nucleic acid in the absence of the test substance. | 2013-07-18 |
20130183349 | METHOD FOR CONTROLLED RELEASE OF PARATHYROID HORMONE FROM CROSS-LINKED HYALURONIC ACID HYDROGEL - A method for locally controlled release of an effective amount of PTH(1-34) by a hyaluronic acid based hydrogel that can injected intra-articularly for the treatment of osteoarthritis is provided. | 2013-07-18 |
20130183350 | IMMUNOGENIC COMPOSITIONS - This disclosure relates to immunogenic compositions comprising an isolated immunogenic | 2013-07-18 |
20130183351 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS - The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 2013-07-18 |
20130183352 | NANOFIBER SCAFFOLDS AND METHODS FOR REPAIRING DAMAGED CARDIAC TISSUE - Compositions are provided comprising a nanofiber scaffold that is seeded with one or more relevant cells and has a basketweave configuration that mimics the structure of a tissue, such as a cardiac tissue. Methods for treating damaged cardiac tissue in a subject are also provided and include applying an effective amount of the composition to damaged cardiac tissue. Methods for making nanofiber scaffold compositions are further provided and include electrospinning a biodegradable polymer onto a mandrel to create a mat of electrospun nanofibers, dividing the mat into nanofiber strips; and weaving the strips into a nanofiber scaffold having a basketweave configuration that mimics the structure of a tissue. | 2013-07-18 |
20130183353 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 2013-07-18 |
20130183354 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT USING TARGETED CARBON NANOTUBES - A method for detecting and/or destroying cancer tumors is based on the concept of associating a linking protein or linking peptide to carbon nanotubes to form a protein-carbon nanotube complex. | 2013-07-18 |
20130183355 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES - Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described. | 2013-07-18 |
20130183356 | IMMUNITY INDUCER - The purpose is to provide an immunity-inducing agent which can be implanted or injected in vivo by a simple operation and is capable of activating the in vivo immunological actions without causing adverse side effects. An immunity-inducing agent comprising β-tricalcium phosphate (β-TCP) having a porosity of 50% or less is implanted or injected in vivo, particularly in the vicinity of a lesion area (non-lesion area) such as cancer. Lymphocytes such as T cells, B cells and NK cells or a dendritic cell can be induced in the vicinity of β-TCP, and a lymphadenoid tissue is formed in which lymphocytes are localized at a high density. Examples of the dosage form of the immunity-inducing agent include particles or granules having a particle or grain size of equal to or greater than 0.05 μm and less than 25 μm, as well as tablets or columellas. | 2013-07-18 |
20130183357 | OXIDATIVELY CROSS-LINKED PROTEIN-BASED ENCAPSULATES - The present invention provides a method of producing a protein-based encapsulate, said method comprising: providing an aqueous solution of a protein that is capable of forming disulfide cross-links; submitting said aqueous solution to a protein activation treatment to produce an aqueous suspension of activated protein aggregates, said suspension having a reactivity of at least 5.0 μmol thiol groups per gram of activated protein aggregates as determined in the Ellman's assay; dispensing said aqueous suspension in a gas or a water-immiscible liquid to produce suspension droplets having a diameter of 0.1-500 μm; and forming disulfide cross-links between the activated protein aggregates by contacting the activated protein aggregates with an oxidizing agent, optionally after said activated protein aggregates have been partially cross-linked by forming disulfide cross-links by means of heat treatment or by pressurization to a pressure in excess of 50 MPa. The aforementioned method offers the advantage that the characteristics of the protein-based encapsulation matrix can be controlled effectively. Furthermore, said method enables the preparation of protein-based encapsulates that very effectively protect the encapsulated components, e.g. against oxidation or moisture. | 2013-07-18 |
20130183358 | LIPOSOMES FOR THE TREATMENT OF TEXTILE MATERIALS - Liposomes with cosmetic and/or dermopharmaceutical ingredients for the care of the skin, scalp and/or hair and their use in washing agents and/or sprays for the treatment of textile materials. | 2013-07-18 |
20130183359 | POLYMERIC COMPOSITIONS CONTAINING IR-EMITTING/ABSORBING ADDITIVES AND SHAPED ARTICLES COMPRISED THEREOF - Polymeric compositions containing additives having properties of emission and/or absorption of radiation in the long infrared region, and articles shaped therefrom are produced, including yarns and textile articles such as fabrics or knits; such additives include organic additives or inorganic fillers which have a capacity for absorption/emission of radiation in the infrared region, in a wavelength range of from 2 μm to 20 μm, and also a polymeric substrate, with the proviso that the inorganic fillers may be selected from among oxides, sulfates, carbonates, phosphates and silicates, and such inorganic fillers having an average particle size of less than 2 μm. | 2013-07-18 |
20130183360 | PETROLATUM COMPOSITION AND PROCESS FOR ITS MANUFACTURE - Petrolatum based compositions (i.e., composition in which the emollient petrolatum comprises greater than or equal to 50% of the composition) are desirable because of the excellent moisturization properties provided by petrolatum. However, it has sensory negatives perceived by consumers. Specifically, because of the oily/greasy and “tacky” (i.e., slightly adhesive or gummy to touch) feel, petrolatum has certain limits to the scope of application. We have found a way to overcome this problem using a copolymer which furthermore avoids the undesirable use of additional oil. A composition is therefore provided comprising: i) 50% to 99.95% by weight petrolatum; ii) greater than 0.05% by weight of a copolymer bearing greater than 70% long chain alkyl. said composition having an enthalpy of between 30 and 65, preferably 40 and 60, even more preferably 45 and 55 J/g, the petrolatum number average crystal size being less than 10 μm, preferably less than 5 μm, more preferably less than 1 μm. | 2013-07-18 |
20130183361 | STRUCTURED ACRYLATE COPOLYMER FOR USE IN MULTI-PHASE SYSTEMS - Disclosed are multi-staged acrylic based core-shell polymers comprising a linear core polymer and at least one subsequently polymerized shell polymer. At least one of the subsequently polymerized shell polymers is crosslinked. The core-shell polymers surprisingly provide desirable rheological, clarity, and aesthetic properties in aqueous surfactant containing compositions, particularly at low pH. The multi-staged acrylic base core-shell polymers can be included in at least one phase of a multi-phase personal care, home care, health care, and institutional and industrial care composition to impart phase stability thereto. | 2013-07-18 |
20130183362 | SYNTHESIS OF ZINC ACRYLATE COPOLYMER FROM ACID FUNCTIONAL COPOLYMER, ZINC PYRITHIONE, AND COPPER COMPOUND - Disclosed is a composition containing zinc ester functional polymer and particulate copper pyrithione, wherein the particles have an average aspect ratio within a range of from about 8 to about 15, where the zinc ester functional polymer and the copper pyrithione are obtained by reacting an acid functional polymer with zinc pyrithione and a copper salt or a copper carboxylate. Also disclosed is an antifouling coating containing such a composition. | 2013-07-18 |
20130183363 | PREVENTION OF INDWELLING DEVICE RELATED INFECTION: COMPOSITION AND METHODS - Catheters used for medical treatment, e.g., hemodialysis are filled with a locking solution, usually heparin between treatments. To prevent infections, antimicrobial or antibiotic substances have been used as locking solution alone or in combination with antithrombotic substances. It has been found that these locking solutions are rapidly washed out from the catheter tip. The invention describes a thixotropic gel that can be used as locking solution. Beneficial, substances, e.g., antimicrobial or antibiotic substances can be added to the gel. A preferred antimicrobial substance is taurolidin alone or in combination with salicylic acid or one of its salts. | 2013-07-18 |
20130183364 | ANTIMICROBIAL PRODUCT AND METHOD - An antimicrobial product is provided in which an antimicrobial substance is encapsulated in capsules suspended within a suspending substance. The antimicrobial substance is released upon abrasion of the surface of the antimicrobial product. The antimicrobial product is used to coat surfaces to provide released antimicrobial substance to the hands of someone touching the surfaces. | 2013-07-18 |
20130183365 | Wound Healing Device and Method - The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof. | 2013-07-18 |
20130183366 | SHEET PREPARATION FOR TISSUE ADHESION - A sheet preparation characterized by that fibrinogen is held on one surface of a sheet-shaped support and thrombin is held on the other surface of the sheet-shaped support where fibrinogen is not held and that fibrinogen and thrombin are held separately from each other, and a process for preparing the same. | 2013-07-18 |
20130183367 | PEPTIDES DES-[ASP1]-[ALA1], ANGIOTENSIN-(1-7) AGONIST AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES - The present invention is related to the peptide Des-[Asp | 2013-07-18 |
20130183368 | P97-ANTIBODY CONJUGATES AND METHODS OF USE - The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers. | 2013-07-18 |
20130183369 | Means of inducing cellular exocytosis and uses thereof - Means, compositions, and uses for triggering exocytosis of lysosomes in living cells. During exocytosis, lysosomes travel to the plasma membrane of the cell and dump their contents outside of the cells, thus removing accumulations of harmful, reactive metabolic by-products, such as lipofuscin. Consequently, cells function better, thus improving their vitality and the vitality of people, animals, and cell cultures. Degenerative diseases can be prevented or reversed. Embodied methods include electrical pulses, sonic vibrations, mechanical pressure, and mixtures of substances, which may include drugs, proteins, antibodies, or liposomes, which can be combined, injected, or administered transdermally or orally. Other embodiments are described and shown. | 2013-07-18 |
20130183370 | SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) AND AN ANTI-CANCER AGENT - Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a C | 2013-07-18 |
20130183371 | SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) AND AN ANTI-CANCER AGENT - Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a C | 2013-07-18 |
20130183372 | METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated. | 2013-07-18 |
20130183373 | METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated. | 2013-07-18 |
20130183374 | SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG - Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided. | 2013-07-18 |
20130183375 | METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated. | 2013-07-18 |
20130183376 | HEPATITIS C VIRUS LIPOSOME VACCINE - The present invention provides a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis C virus NS3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic T lymphocytes, the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer, and the peptide is bound to the surface of the liposome; a cytotoxic T lymphocyte activator containing the peptide-bound liposome; and a hepatitis C virus vaccine. | 2013-07-18 |
20130183377 | SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS - The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen | 2013-07-18 |
20130183378 | CD133 Epitopes - An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders. | 2013-07-18 |
20130183379 | GRAFT COPOLYMER POLYELECTROLYTE COMPLEXES FOR DRUG DELIVERY - Graft copolymer polyelectrolyte complexes are disclosed for the efficient delivery of anionic, cationic or polyelectrolyte therapeutic agents into biological cells, and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such complexes comprise (1) an anionic graft copolymer containing an anionic polymer backbone, with pendent carboxylic acid groups and pendant chains containing amphipathic or hydrophilic polymers covalently bonded to a portion of the pendant carboxylic acid groups, (2) one or more anionic, cationic or polyelectrolyte therapeutic agents, and (3) optionally a liposome optionally containing an additional therapeutic agent. Also disclosed are functional nanoparticles containing the complexes. | 2013-07-18 |
20130183380 | Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-yl)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate - Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described. | 2013-07-18 |
20130183381 | METHODS FOR TREATING MULTIPLE MYELOMA USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL))-ISOINDOLINE-1,3-DIONE IN COMBINATION WITH PROTEASOME INHIBITOR - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2013-07-18 |
20130183382 | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same - The present invention relates to fexofenadine granules, to a composition containing them and to a process for the hot-melt coating of fexofenadine. The process for the hot-melt coating of fexofenadine allows efficient masking of its bitter taste without, however, unacceptably slowing down its dissolution. | 2013-07-18 |
20130183383 | PHARMACEUTICAL COMPOSITIONS FOR CALANOLIDES, THEIR DERIVATIVES AND ANALOGUES, AND PROCESS FOR PRODUCING THE SAME - The present invention relates to pharmaceutical compositions of calanolides, their derivatives and analogues, and process for producing the same having enhanced solubility and bioavailability for oral or parenteral administration. The invention further provides for a method of using the disclosed compositions for the treatment and prevention of retroviral diseases such as human immunodeficiency, specifically HTV-1 and mycobacterial diseases especially tuberculosis infections in mammals, particularly humans. | 2013-07-18 |
20130183384 | IMMEDIATE RELEASE MULTI UNIT PELLET SYSTEM - The present invention relates to a multiple unit pellet system (MUPS) in form of a tablet containing a pharmaceutically active ingredient, characterized in that the MUPS is an optionally coated immediate release pharmaceutical dosage form for oral administration. | 2013-07-18 |
20130183385 | PEPTIDE ANALOGS FOR TREATING DISEASES AND DISORDERS - A peptide having a sequence selected from SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18. Said peptide used for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test. | 2013-07-18 |
20130183386 | PROCESS FOR OBTAINING A RABBIT SKIN COMPRISING BIOLOGICAL ACTIVE SUBSTANCES - The present invention relates to a process for obtaining a rabbit skin containing biologically active substances. The rabbit skin extract is obtained by the process including vaccinating a rabbit subcutaneously with vaccinia virus, feeding the rabbit, killing the rabbit when the skin is inflamed, skinning the rabbit within 15 minutes of death, preserving the rabbit skin at −18 degrees Celsius, extracting a portion of the rabbit skin with a phenol solution at 4° C., processing the rabbit skin extract with an acid and an alkali, eluting the rabbit skin extract and fractioning under a nitrogen atmosphere the eluted portion of the rabbit skin extract. The rabbit skin of the present invention can be used for preparing drugs and health foods. | 2013-07-18 |
20130183387 | Methods for treating pustular conditions of the skin - The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 2013-07-18 |
20130183388 | Novel IDO Inhibitors and Methods of Use Thereof - Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed. | 2013-07-18 |
20130183389 | DIALYSIS PRECURSOR COMPOSITION - The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consist of powder components comprising sodium chloride, at least one dry acid and at least one magnesium salt, and optionally potassium salt, calcium salt, and glucose. According to the invention said at least one magnesium salt and said optional glucose, are present as anhydrous components in said dialysis acid precursor composition. | 2013-07-18 |
20130183390 | SYNERGISTIC PESTICIDE COMPOSITIONS - The present invention relates to compositions that include a combination of one or more pesticides and one or more adjuvants. | 2013-07-18 |
20130183391 | Palm fiber-based dietary supplements - The present invention relates to palm fiber-based dietary supplements. Specifically, the inventions relates to compositions of palm trunk fiber with high antioxidant capability and SOD-like activity, and their uses. The invention further provides for methods of preventing or treating disorders in a subject caused by reactive oxygen chemical species. | 2013-07-18 |
20130183392 | INSECT REPELLANT AND SYSTEM - The present invention is directed to an insect repellant composition comprising geraniol, thyme oil, vanillin, and a castor oil based emulsifier. The insect repellant composition is mechanically aerially dispersed over a region such that it evaporates during dispersement and from the landing surface. In an alternate embodiment, the insect repellant is applied topically. | 2013-07-18 |
20130183393 | COMPOSITION AND METHODS FOR CLOTTING BLOOD - Disclosed herein are compositions and methods for use of such for clotting blood. In one example, a disclosed composition includes at least | 2013-07-18 |
20130183394 | COSMETIC OR DERMATOLOGICAL COMPOSITION FOR TOPICAL APPLICATION - The invention relates to a cosmetic or dermatological composition, preferably purely plant-based, for topical use, containing | 2013-07-18 |
20130183395 | COMPOSITIONS COMPRISING BOTANICALS, INCLUDING THE USE AND METHOD OF USE THEREOF - A composition comprising indole-3-carbinol, milk thistle, schizandra, stinging nettle, hydroxymatairesinol ligands and optionally calcium-d-glucarate and 400 KJ Vitamin D for altering urinary estrone metabolite and preventing breast cancer in pre and post menopausal women | 2013-07-18 |
20130183396 | WETTED TYPE CALIBRATOR FOR MANUFACTURING WINDOW FRAME AND MANUFACTURING DEVICE INCLUDING THE CALIBRATOR - A wetted type calibrator for manufacturing a window frame and a manufactruing device including the same, in which an intensive cooling system having the wetted type calibrator including multiple disk parts is disposed at a next process of an extrusion molding process so as to enhance cooling effect. The wetted type calibrator for manufacturing the window frame includes a housing which accommdates a desired amount of water therein; and a calibrator assembly which is disposed in the housing so that an extruded product formed of a synthetic resin material is passed therethrough. The apparatus for manufacturing the window frame includes an extruder in which functions to a raw mater injected through a hopper is heated and melted in a heating cylinder having a heater and then the melted material is extruded by rotation of a screw; an extrusion die by which the gel-state material supplied through the extruder is formed into a desired shape; a wetted type calibrator which forms a profile shape of the product passed through the extrusion die and also forms the product having a precise dimension and shape; a water tank which cools the extruded product passed through the wetted type calibrator; an extracting device which pulls the extruded product passed through the water tank with constant foce; and a cutting device which cuts the extruded product in a desired size. | 2013-07-18 |
20130183397 | ENGRAVING APPARATUS - An engraving apparatus of rubbing rollers for manufacturing retarder films is provided. The engraving apparatus comprises a body and an engraving end including a plurality of micro-groove structures. The plurality of micro-groove structures of the engraving end are arranged in parallel or irregularly. The engraving apparatus rubs on the rollers using the engraving end in a predetermined direction. Then the predetermined pattern structures are rubbed on the roller. In the rubbing process, the engraving apparatus can rub different pattern structures backwards and forwards directly without to move the engraving apparatus to the starting position of engraving paths. It keeps the manufacturing speed to manufacture the retarder film for saving the process time and the manufactured retarder film with the accuracy. | 2013-07-18 |
20130183398 | SPACER MOLDS WITH RELEASABLE SECUREMENT - A mold for forming a temporary prosthesis has at least two mold members at least partially separable from each other. The at least two mold members cooperatively define a generally enclosed interior cavity for forming the temporary prosthesis. The mold has a securement structure mounted on the at least two mold members for securing the at least two mold members to each other during the forming of the temporary prosthesis. The securement structure is removable from the at least two mold members by hand and without the use of a tool. | 2013-07-18 |
20130183399 | Method for Improving Physical Performance During Physical Exertion - Beverages comprising sodium ion in an amount correlated to the sodium ion concentration of a subject's sweat used to prehydrate before exertion or to restore lost electrolyte and water resulting from physical exertion. Such use can avoid or substantially reduce losses in performance and, in cramp prone individuals, avoid or substantially reduce cramping brought on by physical exertion. | 2013-07-18 |
20130183400 | CEREAL BOWL - The invention relates to a cereal bowl for gradually mixing a solid food and a liquid food for being eaten mixed, comprising an outer container ( | 2013-07-18 |
20130183401 | MICROWAVEABLE PET TREAT PAN AND METHOD OF PREPARING PET TREAT THEREWITH - A pan for microwave preparation of a pet treat for a type of pet comprising a plastic pan consisting essentially of microwavable plastic material and defining at least one pocket for receiving a pet treat mixture, the pocket defining a shape corresponding to the type of pet to be given the pet treat, such that the mixture can be conformed to the shape of, and microwaved in, the pocket to produce a pet treat at home. | 2013-07-18 |
20130183402 | METHOD AND APPARATUS FOR THE RECOVERY OF PVPP AFTER CONTACT WITH A YEAST FERMENTED BEVERAGE BY SEDIMENTATION SEPARATION - A method of preparing a yeast fermented beverage is provided, which method comprises (a) fermenting wort with a biologically active yeast to produce a fermented liquid; (b) combining the fermented liquid with polyvinylpolypyrrolidone (PVPP) particles to bind at least a fraction of the polyphenols and/or proteins contained in the fermented liquid; (c) removing a slurry containing the PVPP particles and yeast from the fermented liquid; (d) separating said slurry into a yeast-enriched fraction and a PVPP-enriched fraction a technique selected from flotation separation, settling separation and separation using a hydrocyclone; (e) regenerating the PVPP particles before, during and/or after the separation by desorbing polyphenols and/or protein from said PVPP-particles; and (f) recirculating the regenerated PVPP particles to step (b). The method can be operated with single use PVPP as well as regenerable PVPP and does not require sophisticated filter hardware for regenerating the PVPP. | 2013-07-18 |
20130183403 | METHOD OF STABILISING YEAST FERMENTED BEVERAGES - A method of preparing yeast fermented beverage is provided, comprising (a) fermenting wort with yeast to produce a fermented liquid containing yeast, alcohol, polyphenols and protein; (b) optionally removing the yeast; (c) combining the fermented liquid with polyvinylpolypyrrolidone (PVPP) particles to bind at least a fraction of the polyphenols and/or proteins, wherein at least 80 wt. % of the PVPP particles have a diameter of 5-300 μm; (d) removing a slurry containing the PVPP particles; (e) filtering the slurry over a filter having a pore size of 0.1-80 μm to produce a PVPP-enriched retentate and a PVPP-depleted filtrate; (f) regenerating the PVPP particles in the PVPP-enriched retentate by desorbing and separating the polyphenols and/or protein from the PVPP-particles; and (f) optionally, further refining and recirculating the regenerated PVPP particles to step (c). The method can be operated with single use PVPP or regenerable PVPP and does not require capacious filter hardware. | 2013-07-18 |
20130183404 | METHOD OF PREPARING AN OAT PROTEIN AND FIBER PRODUCT - A method of preparing an oat protein and fiber product. A base formulation is mixed water to form a slurry. The base formulation has a major amount of an oat material or waxy barley hybrid. At least one enzyme is mixed into the slurry. The at least one enzyme capable of facilitating sugar formation and thinning of the slurry. The slurry is cooked to convert the slurry into a first intermediate product having a DE of between about 20 and 90. The first intermediate product is diluted with water to form a second intermediate product. The second intermediate product is heated. A first solids slurry is recovered from the second intermediate product using a clarifying centrifuge. The first solids slurry is dried to form a dried product. | 2013-07-18 |
20130183405 | Method of Processing Oats to Achieve Oats with an Increased Avenanthramide Content - Producing soluble oat flour with an increased level of avenanthramides by using enzymes to precondition whole oat flour prior to extrusion. | 2013-07-18 |
20130183406 | METHOD FOR PRODUCING FROZEN BREAD DOUGH WHICH DOES NOT REQUIRE THAWING OR FERMENTATION STEP - Provided is shaped frozen bread dough from which a baked bread product having favorable post-baked qualities (taste, texture, flavor, appearance (voluminousness), and the like) can be prepared using a commonly employed baking facility, without requiring a special facility for thawing and fermenting. A bread dough having a continuous, multi-layered structure is prepared by using a cereal flour composition containing yeast and an oil-and-fat composition (roll in oil-and-fat), the bread dough is formed into a desired shape, and then a dent is made on the surface of the thickest portion having the length which is 13% to 70% of the longitudinal length of the shaped article. | 2013-07-18 |
20130183407 | METHOD FOR PRODUCING AN EDIBLE GAS HYDRATE - A method for producing an edible composite of gas hydrate and ice is provided, the method comprising the steps of contacting an aqueous solution with carbon dioxide or nitrous oxide at a sufficiently high pressure to form a gas hydrate, but at a temperature preventing this; and then reducing the temperature of the solution to form the gas hydrate and ice; characterized in that the aqueous solution contains from 0.0001 to 2 wt % of an ice structuring protein. Frozen confections containing gas hydrates and methods for producing them are also provided. | 2013-07-18 |
20130183408 | POLYETHYLENE GLYCOL LACTID COATING ON FRESH EGG - This process is designed to coat fresh chicken eggs with polyethylene glycol-lactide. The process reduces possible microbial content which may be inside fresh eggs while preventing the contamination of the eggs after being laid. It also extends the shelf life while maintaining the quality of the eggs. In addition, the PEG coating lowers the rate of fractures related to the egg shell while being handled, whether that be during storage, when the eggs are transported, or when the eggs are transferred to a market display. | 2013-07-18 |
20130183409 | Dual Component Food Product And Method For Production Thereof - A co-extruded dual component food product having a cereal-based outer component and an inner cream textured component encapsulated within the cereal-based outer component. The cream textured component includes an aqueous phase dispersed in a continuous oil phase. The aqueous phase includes at least partly gelatinised starch. The starch is mixed with water to provide an aqueous phase, which is mixed with an oil phase to provide the cream textured inner component having a first The cereal-based outer component is cooked and the cream textured inner component is injected into the hot cereal based outer component. The starch in the aqueous phase is partly gelatinized to provide the cream textured component with a viscosity greater than the first viscosity. | 2013-07-18 |
20130183410 | NUT AND DRIED FRUIT SNACK FOOD PRODUCT - This application relates to a snack food product, and more particularly, to a snack food product food product that contains just two solid ingredients (nuts and dried fruits) and a syrup. In certain embodiment the snack food product contains pistachios, dried cranberries, agave and brown rice syrup. | 2013-07-18 |
20130183411 | COOKED AND SHELF STABLE STEEL CUT OATMEAL IN A CUP - A cooked steel cut oatmeal product is shelf stable and supplied in a cup. The oatmeal product of the present invention allows people to enjoy a healthful steel cut oatmeal without the hassle and time needed for cooking it. The product of the present invention may simply be warmed and ready to eat while retaining its natural taste and texture. | 2013-07-18 |
20130183412 | TRI-FOLD EGG CARTON FOR JUMBO EGGS - A tri-fold plastic egg carton for protecting jumbo eggs in both oriented and non-oriented positions. A cell base and cell cover are hingedly connected in a closed position with the cover over the base to form a complimentary 2×6 matrix of cell pockets for holding individual eggs. A lid is hingedly connected to another edge of the base for closing over the assembled cover and base. The non-hinged peripheral edges of the base, cover and lid form a trim perimeter having a turned up lip edge, the lip edges mating when the carton is in the closed position to increase the carton strength. The carton can accommodate a full range of jumbo eggs, and accept a variety of smaller size eggs, while fitting within standard cases and half-cases. | 2013-07-18 |
20130183413 | Food Storage Device - A food storage system including an ovenable tray storing a food product therein and an ovenable bag entirely receiving the tray and food product therein. | 2013-07-18 |
20130183414 | EDIBLE FOOD WRAP AND METHOD FOR MAKING SAME - An edible food wrap for a variety of comestible is described. A peeling device is employed to produce a thin, elongated strip of a suitable edible material. The precisely cut strip can then be efficiently and completely deodorized and decolorized by soaking in a PH controlled alkaline water solution. Adding color to the strip is done preferentially with naturally occurring colors added directly to the alkaline water solution. White vinegar added at this time protects the intensity of the color added to the strip. The food wrap is then ready for use, particularly well suited for the outer covering of sushi. | 2013-07-18 |
20130183415 | High Amplitude Corrugated Food Product and Method of Making Same - A high-amplitude corrugated food product and method of making same. The corrugated food product comprises a corrugated surface on opposing surfaces, each surface having a plurality of peaks with substantially equal amplitude values of at least about 2.54 mm. The corrugated food product further comprises a high area moment of inertia of between about 20×10 | 2013-07-18 |
20130183416 | Shell Egg Pasteurization System and Method - A hatch processing control system for a shell egg pasteurizer controls the time and temperature in which batches of shell eggs are held in a pasteurization bath in accordance with a predetermined pasteurization protocol for designated egg size and start temperature. The predetermined pasteurization protocol is preferably statistically verified to optimize batches of eggs having the designated size and start temperature. The system also includes reporting software that generates daily reports to track each respective batch and verify that the batch has been pasteurized according to the statistically verified protocol. | 2013-07-18 |
20130183417 | FOOD PASTEURIZATION DEVICE INCLUDING SPIRALLY WOUND ELECTRICAL CONDUCTOR AND RELATED METHODS - A food pasteurization device may include a food pasteurization chamber having a pair of opposing first and second ends with an enlarged width medial portion therebetween, and a first electrically conductive layer adjacent the first opposing end of the food pasteurization chamber. The food pasteurization device may also include a spirally wound electrical conductor surrounding the food pasteurization chamber and coupled to the first electrically conductive layer. A radio frequency (RF) source may be coupled to the spirally wound electrical conductor. | 2013-07-18 |
20130183418 | METHOD OF INHIBITION OF ENZYMATIC BROWNING IN FOOD USING A SULFINIC ACID COMPOUND - A method of inhibiting enzymatic browning in food involves the contacting of a compound comprising a sulfinic acid with the food. The sulfinic acid comprising compound can be provided from solution, an extract, or in solid form to a food that can lose its appeal to a consumer due to browning, such as cut fruits and vegetables, seafood, or a beverage. The antibrowning agent can be applied to the food by spraying, dusting, dipping, or dissolving, depending upon the form of the food to which the agent is added. The compound comprising a sulfinic acid can comprise an alkysulfinic acid, an arylsulfinic acid, an alkylarylsulfinic acid, or an arylalkylsulfinic acid. | 2013-07-18 |
20130183419 | Enhancement of Potato Tuber Sprouting Inhibitors Using Various Combinations of Agents - Compositions and methods for inhibiting the sprouting of potato tubers are provided. The compositions comprise combinations of i) α,β-unsaturated aliphatic aldehydes, and ketones,C3 to. C14 aliphatic aldehydes and ketones, and/or C3 to C7 saturated or unsaturated primary and secondary aliphatic alcohols; and 2) conventional sprout Inhibitors, The effect of the combinations is additive and/or synergistic, and less of the conventional inhibitor is required to achieve the same or improved levels of sprout inhibition. | 2013-07-18 |
20130183420 | Premium Quality Refrigerated Vegetable Products and Methods of Making Them - The disclosure relates to methods of treating whole, cut, or other processed botanical ingredient(s) in a manner that reduces the load of viable food-contaminating organisms (human or other animal pathogens and food spoilage organisms), preferably without substantially altering one or more of the organoleptic properties of the ingredient(s). The method includes subjecting a botanical foodstuff to a high pressure processing (HPP) treatment and to aseptically sealing the foodstuff within a package that contains a microbistat. Such treatments improve the storage stability of the foodstuff and preferably do not significantly alter one or more organoleptic properties of the botanical ingredient(s). Packaged foodstuffs treated as described herein exhibit beneficial properties, such as retention of taste, appearance, and texture and extended shelf life, relative to non-treated foodstuffs. | 2013-07-18 |
20130183421 | Oil-Filtration System with Oil-Fryer Separation for Automated Food-Fryers - A cooking-oil filtration system and method for automated food-fryers with a solids-removing filter for cleaning cooking oil from the food-fryer which includes and involves an oil/air separator for receiving air-containing oil from the filter and then returning air-separated oil to the food-fryer. In certain highly preferred embodiments the oil/air separator includes a cylindrical inner wall and an inlet conduit configured for tangential entry and spiral flow of oil. In another embodiment, the oil/air separator is a surge tank having upper and lower tank upper portions and conduits facilitating the in-flow of air-containing oil and the gravity out-flow of air-separated oil to the food-fryer. In-flow is preferably driven by a pump upstream of the filter media. | 2013-07-18 |
20130183422 | RECOVERY OF NON-COAGULATED PRODUCT IN RED MEAT FAT REDUCTIONPROCESSES - Disclosed is a method for producing a defatted meat production comprising the steps of: heating ground fatty meat tissue to a temperature below the coagulation temperature of the fatty meat tissue, adding water or steam to the fatty meat tissue, separating the fatty meat tissue in a liquefied fat-containing portion and a defatted meat portion, recovering an aqueous phase from the liquefied fat-containing portion, and adding the aqueous phase to the defatted meat portion, wherein the aqueous phase is concentrated by removal of water prior to the addition to the defatted meat portion. The method increases the functionality of the defatted meat product and incorporates essential proteins and flavours in the final defatted meat product. | 2013-07-18 |